Physician profile
Aliya C May
NPI 1902466402
$7,987.13
in general payments reported to CMS, 2019-2025
18 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,394 · 2022: $548 · 2023: $2,384 · 2024: $1,811 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,900 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,900.08 |
| Education | $144.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,571.06 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $1,369.50 | 2021-2025 | |
| Axsome Therapeutics, INC. | $1,209.86 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $1,098.66 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $863.05 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $592.63 | 2021-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $286.70 | 2021-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $261.75 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $214.46 | 2023-2024 | Caplyta |
| Lundbeck LLC | $199.46 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $169.94 | 2022-2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2024 | Abilify Maintena |
| Jazz Pharmaceuticals INC. | $24.41 | 2021 | |
| Sunovion Pharmaceuticals INC. | $22.37 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.50 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.43 | 2023 | Rybelsus, Ozempic |
| Eisai INC. | $16.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aliya May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.